Trevena Inc

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders. Its lead product candidates include OLINVYK (oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for managing moderate-to-severe acute pain; TRV734, a small molecule G protein biased MOR ligand that has completed Phase I studies for moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.